下肢周辺動脈疾患患者の歩行能力に対するテルミサタン効果: TELEX ランダム化臨床試験
Mary M McDermott1, Lydia Bazzano2, Charlotte A Peterson3
1Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
JAMA
|October 4, 2022
まとめ
テルミサルタンは,周辺動脈疾患 (PAD) の患者に歩行距離を改善しませんでした. この研究では,PAD患者の6分歩行距離を増加させるのにテルミサルタンによる有意な効果は認められませんでした.
科学分野:
- 心血管医学
- 薬理学について
- 臨床試験
背景:
- 周辺動脈疾患 (PAD) は,下肢の機能と歩行を著しく損なう.
- テルミサルタンのようなアニオテンシン受容体阻害剤は,PADに関連する異常を逆転させる可能性があることが示されています.
研究 の 目的:
- 下肢PADの患者における6分歩行距離の改善におけるテルミサタン効果を評価する.
- テルミサルタンとプラセボの効果を6ヶ月の追跡期間で比較する.
主な方法:
- PADの114人の参加者を対象とした ダブルブラインド ランダム化臨床試験です
- 参加者は,テルミサルタンまたはプラセボを6ヶ月間,監督された運動と併用して投与された.
- 測定された主なアウトカムは,6分間の歩行距離の変化でした.
主要な成果:
- テルミサルタンは,プラセボと比較して,6分間の歩行距離を有意に改善しなかった (調整された差: - 16. 8 m; P=. 08).
- トレードミルの歩行距離と機能的スコアを含む二次的なアウトカムでは有意な改善は見られなかった.
- PADに関連したイベントのために入院は,両方のグループで参加者の小さな割合で発生しました.
結論:
- テルミサルタンは,外周動脈疾患の患者の歩行能力の改善に有意な効果を示さなかった.
- PAD患者の歩行能力を高めるためにテルミサルタンを使用する現在の証拠は支持しません.
さらに関連する動画
08:42Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
Published on: October 22, 2014
27.4K
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
12.4K
関連する概念動画
01:27Peripheral Artery Disease III: Interprofessional Care
22
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
22
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
26
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
26
01:26Peripheral Artery Disease IV: Nursing Management
24
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
24
01:23Peripheral Artery Disease V: Postoperative Nursing Management
17
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
17
01:30Peripheral Artery Disease I: Introduction
24
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
24
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
872
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
872